Cancer Communications

Papers
(The TQCC of Cancer Communications is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
529
Issue Information501
Issue Information320
Kindlin‐1 drives early steps of breast cancer metastasis302
Correction to “Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges”229
Defining and tracing subtypes of patient‐derived xenograft models in pancreatic ductal adenocarcinoma219
Loss of CDKN1B induces an age‐related clonal hematopoietic disorder via Notch2 activity dysregulation218
Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin‐bundling activity and tumor metastasis in esophageal squamous cell carcinoma204
Issue Information194
180
Nine‐fold variation of risk of advanced colorectal neoplasms according to smoking and polygenic risk score: Results from a cross‐sectional study in a large screening colonoscopy cohort178
173
Age‐specific effectiveness of primary human papillomavirus screening versus cytology in a cervical cancer screening program: a nationwide cross‐sectional study160
Single‐cell transcriptomics and epigenomics point to CD58‐CD2 interaction in controlling primary melanoma growth and immunity152
Combined local therapy and CAR‐GPC3 T‐cell therapy in advanced hepatocellular carcinoma: a proof‐of‐concept treatment strategy143
Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study138
The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of colorectal cancer, 2024 update137
Current status and perspectives of esophageal cancer: a comprehensive review130
Signaling pathways in cancer‐associated fibroblasts: recent advances and future perspectives122
Research trends of cancer metabolism: analysis from a Chinese perspective121
Issue Information121
118
p38γ and p38δ as biomarkers in the interplay of colon cancer and inflammatory bowel diseases114
Efficacy and safety of first‐line sintilimab plus anlotinib versus chemotherapy for metastatic non‐small cell lung cancer: a phase II, open‐label, randomized controlled trial110
Impact of pre‐existing cardiometabolic diseases on metastatic cancer stage at diagnosis: a prospective multinational cohort study103
Validation of different personalized risk models of chemotherapy‐induced nausea and vomiting: results of a randomized, double‐blind, phase III trial of fosaprepitant for cancer patients treated with h103
102
Comparative single‐cell analysis of esophageal cancer subtypes reveals tumor microenvironment distinctions explaining varied immunotherapy responses97
EXPRESSION OF CONCERN: Discovery of a Novel Viroid‐Like Circular RNA in Colorectal Cancer95
Issue Information89
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5‐year update of 81
A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer79
Partial hepatectomy versus interventional treatment in patients with hepatitis B virus‐related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinica77
Single‐cell transcriptomics provides insights into the origin and immune microenvironment of cervical precancerous lesions70
Development and validation of an artificial intelligence model for predicting post‐transplant hepatocellular cancer recurrence69
Residual circulating tumor DNA after adjuvant chemotherapy effectively predicts recurrence of stage II‐III gastric cancer66
N 6 ‐methyladenosine‐regulated exosome biogenesis orchestrates an immunosuppressive pre‐metastatic niche in gastric cancer peritoneal metastas64
Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer63
HSF1 facilitates the multistep process of lymphatic metastasis in bladder cancer via a novel PRMT5‐WDR5‐dependent transcriptional program61
Multifunctional inorganic nanomaterials for cancer photoimmunotherapy59
Oral transforming growth factor‐beta receptor 1 inhibitor vactosertib promotes osteosarcoma regression by targeting tumor proliferation and enhancing anti‐tumor immunity57
Nasopharyngeal carcinoma treatment paradigm after HK0501 – a potential way forward57
Issue Information56
55
Association of previously irradiated stable brain metastases with outcomes of atezolizumab‐treated non‐small cell lung cancer: A pooled analysis of individual patient data from three randomized trials54
Cover Image, Volume 45, Issue 654
54
Acquired RD3 loss regulates immune surveillance in high‐risk and therapy defying progressive neuroblastoma52
Cover Image, Volume 42, Issue 152
Impact of small molecule‐mediated inhibition of ammonia detoxification on lung malignancies and liver metabolism50
Intercellular communications and metabolic reprogramming as new predictive markers for immunotherapy responses in gastric cancer49
Comprehensive DSRCT multi‐omics analyses unveil CACNA2D2 as a diagnostic hallmark and super‐enhancer‐driven EWSR1::WT1 signature gene48
FOXO1 or not FOXO1: that is the question48
Targeting IL‐17A to manage immunotherapy‐induced toxicity in melanoma46
Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis46
Association between antipsychotic agents and risk of lung cancer: a nested case‐control study45
Ubiquitination in cancer: mechanisms and therapeutic opportunities45
A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX245
Harnessing chimeric antigen receptor macrophages against solid tumors44
A strong internal promoter drives massive expression of YEATS‐domain devoid MLLT3 transcripts in HSC and most lethal AML44
Novel molecular mechanisms of immune evasion in hepatocellular carcinoma: NSUN2‐mediated increase of SOAT2 RNA methylation43
Incidence of and survival with bone and soft tissue sarcoma: A nation‐wide study over four decades43
Antitumoral effects of cannabis in Notch1‐mutated T‐cell acute lymphoblastic leukemia41
Issue Information40
First‐line serplulimab plus chemotherapy in extensive‐stage small‐cell lung cancer: Updated results and biomarker analysis from the ASTRUM‐005 randomized clinical trial40
Correction to: ZNF582 hypermethylation promotes metastasis of nasopharyngeal carcinoma by regulating the transcription of adhesion molecules Nectin‐3 and NRXN338
Low household income and income volatility increase risk of lung cancer: A nationwide retrospective cohort study37
m6A‐modified EHD1 controls PD‐L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma36
Enhanced selection of people for lung cancer screening using AHRR (cg05575921) or F2RL3 (cg03636183) methylation as biological markers of smoking exposure35
Correction to “Circulating tumor cells share RNA modules with early embryo trophectoderm and with metastatic cancer”34
Transcriptomic analyses of localized prostate cancers of East Asian and North American men reveal race‐specific luminal‐basal and microenvironmental differences34
Long‐term outcomes of intraoperative radiotherapy for early‐stage breast cancer in China: a multicenter real‐world study33
Development of antibody‐drug conjugates in cancer: Overview and prospects33
Breast cancer: an up‐to‐date review and future perspectives32
An HGF‐dependent positive feedback loop between bladder cancer cells and fibroblasts mediates lymphangiogenesis and lymphatic metastasis32
Genomic information of children with malignant brain tumors for the prediction of length of hospitalization32
Inhibition of mTOR attenuates the initiation and progression of BRCA1‐associated mammary tumors30
Genomic characterization reveals distinct mutation landscapes and therapeutic implications in neuroendocrine carcinomas of the gastrointestinal tract30
4‐1BB transcriptomic expression patterns across malignancies: Implications for clinical trials of 4‐1BB agonists30
circCAPRIN1 interacts with STAT2 to promote tumor progression and lipid synthesis via upregulating ACC1 expression in colorectal cancer29
Gene expression profiling improves prognostication by nomogram in patients with soft‐tissue sarcomas29
Breaking barriers: The cGAS‐STING pathway as a novel frontier in cancer immunotherapy29
Long‐term antibiotic use and risk of hepatocellular carcinoma later in life: a nationwide cohort study of 9.8 million participants29
Neuroinflammation drives apathy in cancer cachexia29
Spatial metabolomics for evaluating response to neoadjuvant therapy in non‐small cell lung cancer patients28
Issue Information27
The E3 ubiquitin ligase HUWE1 acts through the N‐Myc‐DLL1‐NOTCH1 signaling axis to suppress glioblastoma progression27
Issue Information27
Cover Image, Volume 44, Issue 427
27
Sunitinib in metastatic renal cell carcinoma: clinical outcomes across risk groups in a Turkish Oncology Group Kidney Cancer Consortium27
N‐acetyltransferase 10 promotes colon cancer progression by inhibiting ferroptosis through N4‐acetylation and stabilization of ferroptosis suppressor protein 1 (FSP1) mRNA27
Single‐cell and bulk transcriptomics identifies a tumor‐specific CD36+ cancer‐associated fibroblast subpopulation in colorectal cancer27
Knowing nodal Rouviére: the power of human intelligence in toxicity reduction27
Galectin 3‐binding protein (LGALS3BP) depletion attenuates hepatic fibrosis by reducing transforming growth factor‐β1 (TGF‐β1) availability and inhibits hepatocarcinogenesis26
Combination of photodynamic therapy and stimulator of interferon genes (STING) agonist inhibits colorectal tumor growth and recurrence26
Breaking barriers: Smart vaccine platforms for cancer immunomodulation26
Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy25
Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins25
Issue Information25
Pancreatic cancer survival trends in the US from 2001 to 2014: a CONCORD‐3 study25
DNA methylation signature predicts cancer response to demethylation agents from profiling diverse cancer cell lines25
Effect of neutrophils on tumor immunity and immunotherapy resistance with underlying mechanisms24
Issue Information24
Tumor microenvironment signaling and therapeutics in cancer progression24
Cover Image, Volume 43, Issue 624
Ex vivo STAT3 phosphorylation in circulating immune cells: a novel biomarker for early cancer diagnosis and response to anti‐PD‐1 therapy23
Leptin‐mediated suppression of lipoprotein lipase cleavage enhances lipid uptake and facilitates lymph node metastasis in gastric cancer22
Beyond success: unveiling the hidden potential of radiotherapy and immunotherapy in solid tumors22
Targeting ferroptosis resistance resensitizes metastatic HR+HER2 breast cancer cells to palbociclib‐hormone therapy21
Advanced precision modeling reveals divergent responses of hepatocellular carcinoma to combinatorial immunotherapy21
A single measurement of fecal hemoglobin concentration outperforms polygenic risk score in colorectal cancer risk assessment21
21
Single‐cell‐eQTL mapping in circulating immune cells reveals genetic regulation of response‐associated networks in lung cancer immunotherapy21
20
The regulatory roles and clinical significance of glycolysis in tumor20
Perivascular localized cells commit erythropoiesis in PDGF‐B‐expressing solid tumors20
Enhancing sensitivity of triple‐negative breast cancer to DNA‐damaging therapy through chemical inhibition of the m6A methyltransferase METTL320
Proteomic identification of new diagnostic biomarkers of early‐stage cutaneous mycosis fungoides19
Infection complications in febrile chimeric antigen receptor (CAR)‐T recipients during the peri‐CAR‐T cell treatment period examined using metagenomic next‐generation sequencing (mNGS)19
Real‐world outcomes of niraparib treatment in patients with ovarian cancer: a multicenter non‐interventional study in China19
Issue Information19
Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients19
Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors18
In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high‐throughput personalized drug discovery17
The SARS‐CoV‐2 spike protein induces lung cancer migration and invasion in a TLR2‐dependent manner17
Targeting N4‐acetylcytidine suppresses hepatocellular carcinoma progression by repressing eEF2‐mediated HMGB2 mRNA translation17
Issue Information17
HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism17
Ferroptosis in cancer and cancer immunotherapy17
Concurrent chemoradiotherapyof different radiation doses and different irradiation fields for locally advanced thoracic esophageal squamous cell carcinoma: A randomized, multicenter, phase III clinica17
Evolution of tumor microenvironment in colorectal liver metastases under treatment stress17
Lysosomal TMEM9‐LAMTOR4‐controlled mTOR signaling integrity is required for mammary tumorigenesis17
Single‐cell atlas reveals a distinct immune profile fostered by T cell‐B cell crosstalk in triple negative breast cancer17
Smoking, smoking cessation, and survival after cancer diagnosis in 128,423 patients across cancer types16
Dlk1 is a novel adrenocortical stem/progenitor cell marker that predicts malignancy in adrenocortical carcinoma16
Unraveling the routes to distant metastases in colorectal cancer: Tumor deposits and lymph node metastases as the gateway16
NHE7 upregulation potentiates the uptake of small extracellular vesicles by enhancing maturation of macropinosomes in hepatocellular carcinoma16
Discovery of a novel viroid‐like circular RNA in colorectal cancer16
0.045245170593262